RA Capital Management is a Boston-based investment firm that provides multi-stage capital to public and private healthcare, life sciences, and planetary health companies. The firm supports management teams from early seed rounds to later financings, seeking to drive value through scientific and clinical data, product development, and commercialization. It complements capital with value-added services such as board representation, executive recruitment, and market intelligence through its TechAtlas research platform. The company also operates Raven, a healthcare incubator that helps entrepreneurs build biomedical ventures, and emphasizes a collaborative, data-driven approach and long-term relationships. RA Capital pursues social responsibility by advocating for affordable medicines and industry advancement, and it invests across U.S. and European opportunities, including early-stage and growth-stage rounds.

OrbiMed is a global healthcare investment firm based in New York that funds companies across the healthcare spectrum. It uses multiple strategies, including private equity for startups and growth-stage companies, private credit and royalty financing for intellectual property and medical diagnostics, and public equity investments. The firm targets biopharmaceuticals, biotechnology, medical devices, diagnostics, digital health, and health IT, supporting development of new therapies and health technologies. OrbiMed operates internationally with offices in major markets and manages substantial assets across public and private investments, staffed by a team of professionals to identify opportunities and support portfolio companies.

SOSV is a global venture capital firm that provides early-stage and seed investments alongside structured accelerator programs and deeply resourced facilities to accelerate product development. Focused on deep tech, human and planetary health, and cross-border software, SOSV backs startups from pre-seed onward and runs programs that accelerate technical development, regulatory strategy, and fundraising. The firm maintains labs and engineering spaces with specialist staff in multiple regions, including the United States and Asia, to support portfolio companies in biosafety, chemistry, mechatronics, analytics, and electrical engineering. Programs such as HAX and other live events offer founders access to prototyping, testing, and investor networks. Annually, SOSV makes around sixty pre-seed investments (up to roughly $550k each) and participates in numerous follow-on rounds, leveraging a global portfolio and extensive co-investor network to help deeply technical startups scale and reach markets.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It invests in technology, consumer, and healthcare companies at early and growth stages, providing hands-on support and strategic resources in addition to capital. The firm has backed hundreds of portfolio companies and has a record of exits through IPOs and M&A, including unicorn and super unicorn companies. It maintains an international presence through a U.S. team established in 2017, with offices in Cambridge, Seattle, and San Francisco to support healthcare and life sciences entrepreneurs and help portfolio companies scale globally. Qiming emphasizes sector knowledge, founder collaboration, and a long-term partnership approach to drive milestone achievements and create lasting value.

Eli Lilly and Company is a global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of medicines for human health. It operates manufacturing facilities in the United States, Puerto Rico, and about 25 other countries, with products sold in approximately 135 countries. The company also conducts research in animal health, including efforts to improve disease treatments in animals and the efficiency of animal food production. Its therapeutic focus includes neuroscience, cardiometabolic diseases, cancer, and immunology, with a portfolio of medicines addressing conditions such as cancer, diabetes, autoimmune disorders, and neurodegenerative diseases. Eli Lilly and Company is committed to high standards of safety and quality in manufacturing and to expanding access to therapies through global operations and patient support initiatives.

The European Innovation Council is a Brussels-based European Union organization established in 2018 to support deep‑tech innovation by helping startups, researchers and technology transfer activities move ideas toward market. It operates a portfolio of programs including Pathfinder, Accelerator, Transition, STEP Scale Up and Pre-Accelerator, and collaborates with partners to provide funding, mentorship and resources across the innovation lifecycle. The council emphasizes high-impact, science‑driven technologies with broad societal benefit and promotes inclusion, with initiatives to involve women‑led projects. It engages the wider ecosystem through awards, events and community initiatives and monitors impact through data platforms. By coordinating with private investors and other stakeholders, it aims to accelerate the scale-up of European deep‑tech firms and strengthen Europe’s position in global technology leadership.

Alumni Ventures is a venture capital firm based in Manchester, New Hampshire, with offices in New York, Boston, Menlo Park, Chicago, London, and Tokyo. It enables accredited investors, especially alumni networks, to access diversified venture opportunities by co-investing alongside leading venture capital firms. Through funds, syndicates, and investing clubs, it sources opportunities across stages and geographies, conducts rigorous due diligence, and aims for transparent, founder-friendly support. The firm backs a diversified portfolio of startups, including more than 1,600 companies, and has attracted substantial committed capital and a large community of individual investors, underscoring its mission to democratize access to venture capital while partnering with established VC firms.

General Catalyst is a venture capital firm that funds early-stage and growth companies across sectors including consumer, enterprise software, fintech, crypto, and healthcare. Based in San Francisco with offices in Cambridge, Massachusetts and other locations, it provides capital and strategic guidance to help entrepreneurs build scalable, durable businesses. The firm emphasizes the use of technology, including artificial intelligence, to accelerate growth and drive meaningful impact. General Catalyst partners with management teams to support product development, go-to-market strategies, and organizational growth, aiming to back companies with potential for wide adoption and long-term value creation, rather than focusing solely on near-term exits.

Novo Nordisk is a global healthcare company focused on discovering, developing, and delivering medicines for serious chronic diseases, with a core emphasis on diabetes care. The organization produces and distributes insulin and other therapies aimed at treating diabetes and related conditions, while investing heavily in scientific research and biopharmaceutical innovation. Through partnerships and sustained commitments to accessibility, Novo Nordisk seeks to improve patient outcomes and support health systems worldwide. The company operates across many markets, supported by its production of insulin pens and a broad portfolio addressing obesity, rare blood and endocrine disorders, and other chronic diseases. It pursues long-term social responsibility and sustainability as integral to its business model.

New Enterprise Associates is a United States-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across multiple stages, from seed to growth and IPO, and provides strategic support in product development and market expansion. The firm targets sectors including software, AI, consumer technology, digital health, life sciences, and energy technology, and pursues opportunities worldwide. NEA emphasizes long-term partnerships with founders, drawing on domain expertise and a broad network to help portfolio companies scale. It maintains a diverse portfolio across the United States, Asia and other regions, reflecting a global approach to venture investing.

Morningside Group is a venture capital firm founded in 1986, originally established as a family office for the Chan family, and is based in the greater Boston area. The firm makes venture investments in companies with novel science and technology, pursuing a long-term, patient approach to company-building and emphasizing ethical practices. Its investment focus spans life sciences, digital health, artificial intelligence, materials science, and information technology. In addition to its investment activities, Morningside supports charitable initiatives in education, research, and healthcare, with partnerships including the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

Founded in 1985, The Invus Group is a global private equity firm that partners with entrepreneurs, founders and management teams across the company lifecycle. Blending a family-office approach with multi-strategy investing, it supports transformative growth in sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education and medical devices. The firm pursues long-term value creation through strategic insight, capital and execution, investing in companies from early stages to mature businesses and providing both lead investments and co-investments in private transactions worldwide. It maintains a global footprint with offices in New York, London, Paris and Hong Kong and has a flexible structure designed to align incentives with partners over time.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven investments in life sciences, biotechnology, medical technologies, and related fields. The firm backs companies at multiple stages, often co-founded with scientists and entrepreneurs, aiming to translate academic research and national laboratory innovations into therapies, diagnostics, and other breakthrough technologies. ARCH emphasizes deep involvement, technical expertise, and a wide network to support founders from early development through later rounds, acting as a partner rather than a passive investor. With a focus on markets centered in the United States and North America, the firm frequently funds startups emerging from universities and research institutions and has built a track record of helping scientists bring innovations to market.

Deerfield Management is a New York City-based healthcare investment and information platform that advances health outcomes through investment, research, and philanthropy. The firm manages strategies across public and private markets in biotechnology, pharmaceuticals, diagnostics, healthcare services, and medical devices, and supports early-stage innovation through strategic partnerships and dedicated facilities that foster scientific discovery. It operates a philanthropic foundation funding education and broader healthcare access. Leveraging AI-driven intelligence, data, and market research, Deerfield connects capital with researchers, developers, and clinical opportunities, integrating its investment activity with in-building labs and Cure hub that house portfolio companies and collaborations with health systems to accelerate breakthroughs.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. It provides seed through growth capital to life science and technology companies developing breakthrough therapies, diagnostics, research tools, agrifoodtech, agtech, digital health, and related platforms. Backed by the parent company’s industry experience and scientific advisory network, the firm leverages long-standing relationships and domain expertise to support early to growth-stage ventures aiming to translate scientific advances into practical healthcare and technology solutions.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. The firm manages approximately $5.8 billion in assets under management and has invested in over 290 public and private healthcare companies worldwide. Its multi‑fund platform covers growth equity, private equity including buyouts, venture capital, and public equity, and it makes investments across biotechnology, pharmaceuticals, medical devices, and healthcare services in major markets, with a focus on the United States and China. The team comprises about 50 professionals including physicians, scientists, entrepreneurs, operating executives, and industry experts who collaborate to build and grow high‑quality healthcare companies.

Khosla Ventures is a California-based venture capital firm founded in 2004 that provides capital and strategic support to technology-driven startups across early- to late-stage cycles. It pursues opportunities in AI, digital health, healthcare technologies, sustainability, fintech, consumer and enterprise technology, and other frontier areas, focusing on innovative business models and world-class teams. The firm emphasizes a contrarian, long-term approach and seeks to help entrepreneurs address meaningful societal and economic challenges through science, technology, and design.

Antler is a global venture capital firm and startup incubator based in Singapore that invests in early-stage technology companies and supports startups across sectors including healthcare, finance, consumer, and software. It builds a worldwide community of co-founders and provides access to talent, mentors, and expert advisors, along with expansion support and capital to help teams form, validate business models, and grow internationally. Antler emphasizes long-term partnerships with portfolio companies, continuing to back ventures through growth stages as they scale.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It focuses on technology and healthcare, investing in seed and early-stage companies in the United States and pursuing life sciences and emerging technologies. The firm provides funding and strategic guidance to entrepreneurs with the aim of building enduring, high-growth companies. Its portfolio has included notable technology and biotech names such as Apple, Illumina, Gilead Sciences, and DoubleClick. Venrock maintains offices in Palo Alto, California, and New York, and emphasizes long-term partnerships with founders to accelerate innovation.

Samsara BioCapital is a Palo Alto, California-based biotechnology investment firm founded in 2016 that focuses on supporting transformative therapeutics. The firm seeks opportunities in the healthcare sector across the United States and invests in biotechnology companies with the potential to advance patient care. With a team drawn from scientific, medical, and business backgrounds, Samsara BioCapital aims to accelerate the development and commercialization of innovative drugs through strategic partnerships and hands-on collaboration. The approach emphasizes rigorous scientific evaluation and value creation for portfolio companies, helping entrepreneurs turn ideas into therapies with meaningful patient impact.

High-Tech Gründerfonds is a Germany-based venture capital firm established in 2005 that funds early-stage technology startups in Germany. Based in Bonn with an office in Berlin, it supports companies across software, information technology, digital and industrial tech, life sciences, chemistry, IoT, energy, and related fields by providing initial capital and subsequent funding, complemented by active guidance from investment managers. The firm typically acts as a lead investor and cooperates with other investors to help portfolio companies advance from concept to market, with a focus on startups that have begun commercial operations. By combining financing with hands-on support, HTGF aims to help high-potential founders develop their technology, validate products, and scale within the German market.

F-Prime Capital is a Cambridge, Massachusetts-based venture capital firm with a longstanding history of backing early- and growth-stage companies across life sciences and technology. The firm focuses on healthcare including therapeutics, medtech, and healthtech, as well as technology sectors such as enterprise software, fintech, frontier tech, and crypto ventures. Its team combines scientists, engineers, physicians, operators, and investors to provide hands-on support and strategic guidance designed to accelerate scalable growth. With a global footprint, F-Prime engages with portfolio companies across the Americas, Europe, and Asia, and maintains relationships with a wide network of industry experts to help startups advance from concept to market.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco. It invests across the healthcare sector, including life sciences, biotechnology, pharmaceuticals, and medical devices, at all stages with an emphasis on discovery and development of novel therapeutics. The firm operates globally with offices in Canada, the United States, and Europe, delivering hands-on support to portfolio companies through in-house scientific and operating expertise. Versant pursues collaborative partnerships with entrepreneurs to translate research into clinical and commercial success and has a track record of portfolio companies achieving successful acquisitions or IPOs. The firm is registered as an investment adviser.

Andreessen Horowitz is a Menlo Park, California-based venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz. It funds technology startups across seed to late stages, with investments spanning software, cloud infrastructure, enterprise software and services, consumer internet, fintech, artificial intelligence, crypto, infrastructure, and biotechnology at the intersection of computer science and life sciences. The firm emphasizes supporting portfolio companies through growth and strategic partnerships and maintains a broad tech-focused investment approach, aiming to add value beyond capital.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focusing on life sciences. It finances start-ups, early-stage companies, corporate spin-offs, and occasional turnarounds in biopharmaceuticals, biotech, medical devices, and related areas. The firm often acts as a lead or cornerstone investor and is frequently the first institutional backer in Series A rounds, maintaining an active role including board seats from formation through exit. It pursues global opportunities and emphasizes thorough due diligence on portfolio companies, including management and intellectual property considerations. The firm was established in 1972.

Redmile Group is a San Francisco based investment firm specializing in healthcare, life sciences and related technology sectors. It pursues venture, growth, and crossover investments and provides strategic capital and operating experience to portfolio companies, supporting growth initiatives, acquisitions, and strategic partnerships. With offices in San Francisco and New York, the firm takes a hands-on approach, applying deep industry knowledge and networks to help portfolio companies scale and create long-term value for investors.

Pfizer is a leading global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines to address unmet medical needs. It maintains a broad portfolio across prescription medicines, vaccines, and treatments spanning internal medicine, inflammation and immunology, oncology, and other therapeutic areas, and it operates a sizable pipeline of investigational products with potential to address major diseases. The company conducts extensive global sales, with international markets contributing a substantial share of revenue, and it emphasizes scientific innovation, transparency, patient access, and ethical business practices. Its well-known products include Prevnar 13 and Eliquis, among others, and it continues to invest in research and development to advance new therapies. Based in the United States, Pfizer has a long history dating back to the 19th century and maintains a global footprint through manufacturing, partnerships, and philanthropic initiatives aimed at improving health outcomes worldwide.

Right Side Capital Management is a San Francisco-based venture capital firm founded in 2012 that targets early-stage, capital-efficient technology startups in the United States and Canada. The firm employs a data-driven, quantitative approach to investment decisions and aims for rapid yes-or-no conclusions, often within two weeks. Typical rounds encompass small checks in the low hundreds of thousands, with the potential for larger commitments in exceptional cases, and a portfolio-wide strategy that emphasizes diversification. Beyond capital, it provides hands-on mentorship in areas such as sales, marketing, and fundraising, leveraging a network of investors and seasoned operators to support portfolio companies after investment. The firm focuses on teams still refining product-market fit, including those outside traditional tech hubs, and seeks to help founders scale efficiently through structured operational support and transparent decision processes.

Gaingels is a venture capital organization focused on supporting LGBTQ+ founders and leaders and their allies. It invests across stages and industries, building a global portfolio of 130+ companies and deploying around $70 million in capital. Beyond funding, Gaingels helps portfolio companies recruit diverse C-suite and board talent and fosters a global community of investors, operators, and entrepreneurs working toward inclusive leadership and positive social change through business.

Forbion is a global venture capital firm based in Naarden, Netherlands, focused on biotech innovations and sustainable solutions to improve human and planetary health. It invests across human health, planetary health and the bioeconomy, spanning pre-clinical, early clinical and growth stages, and combines company building with venture capital while integrating ESG principles. With two decades of experience and about €5 billion under management across 11 funds, Forbion backs companies in Europe and North America across life sciences, pharmaceuticals and biotechnology sectors.

SV Health Investors is a private equity and venture capital firm that focuses on healthcare and life sciences, including biotech, therapeutics, and medtech. Founded in 1993 as SV Life Sciences, the firm operates globally with offices in Boston, San Francisco, and London and maintains a long US and Europe track record. It funds companies across stages, partnering with entrepreneurs to build breakthrough treatments and technologies, and provides strategic guidance and industry expertise to help portfolio companies grow and pursue IPOs or strategic transactions. With a team of over 50 professionals, SV Health Investors emphasizes value creation across its healthcare investments and seeks to transform healthcare through its portfolio.

Kurma Partners is a Paris-based European investment firm that finances innovation in healthcare and biotechnology. It backs companies across development stages, from early research to expansion, with a focus on therapeutic solutions, diagnostics, healthtech and medtech, as well as digital health. Operating across Europe, it collaborates with research institutes, hospitals and seasoned entrepreneurs to translate scientific advances into clinical and commercial products. The company invests in life sciences, pharmaceuticals and related technologies, emphasizing sustainable and responsible investing and close collaboration with research centers and entrepreneurs to accelerate breakthroughs in healthcare and create long-term value.

8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies and build long-term value. Headquartered in San Francisco, the firm pursues industry-wide impact by backing companies across sectors such as healthcare, AI, cybersecurity, enterprise software, manufacturing, logistics, and energy, spanning seed to later-stage rounds. It emphasizes long-term partnerships and aims to enable industry transformation by supporting platforms and innovations that can replace legacy infrastructure. The firm also supports programs and communities that foster entrepreneurship and positive-sum value creation. Through its investments, 8VC seeks to advance breakthroughs that address critical challenges in life sciences and healthcare, while pursuing responsible growth and societal benefit.

Mission BioCapital is a life sciences venture capital firm established in 2009 and based in Cambridge, Massachusetts, that funds early-stage biotechnology companies and supports them through clinical development. The firm emphasizes mentorship and practical assistance, offering entrepreneurs access to laboratory space, incubator networks, and programs designed to accelerate progress and secure follow-on funding. Its approach combines capital with hands-on guidance across discovery, development, and commercialization, leveraging a history of supporting dozens of startups. Through a broad ecosystem in the United States and Europe, Mission BioCapital aims to translate scientific discoveries into tangible solutions by pairing funding with operational support, expert advice in areas such as drug discovery, legal, and accounting, and strategic mentorship to help portfolio companies reach milestones and attract subsequent investment.

Ben Franklin Technology Partners of Southeastern Pennsylvania is a nonprofit organization founded in 1982 that strengthens the Philadelphia region's technology ecosystem by providing capital, strategic guidance, and professional connections to technology startups and growth companies across Philadelphia, Bucks, Delaware, Chester, and Montgomery counties. It serves as a seed-stage capital provider and investor across information technology, health, and physical sciences, advancing technology commercialization through university–industry partnerships and regional initiatives. The organization aims to accelerate innovation, create jobs, and build a robust entrepreneurial community by offering funding, mentorship, and access to a broad network of resources.

StartUp Health is a global organization and community founded in 2011 that unites health startups, scaleups, funders, thought leaders, and policymakers to accelerate healthcare innovation. It operates a network and programs called Health Moonshot Communities, supports more than 330 companies across six continents and 26 countries, and provides members with access to a network, programs, media content, and events to advance digital health, biotech, and life sciences solutions. The organization aims to improve health outcomes by fostering collaboration, strategic growth, and the pursuit of ambitious health moonshots such as improving access to care, curing disease, ending cancer, and advancing women's and children's health.

Deep Track Capital is a biotechnology investment firm based in Greenwich, Connecticut. It focuses on the life sciences and biotech sector, forging partnerships with management teams of innovative public and pre-IPO biotechnology companies, and aims to invest time, expertise, and its network alongside capital to support partners. The firm seeks to lead transactions while forming large syndicates and to participate in rounds led by other qualified investors.

Logos Capital is a San Francisco-based biotechnology investment firm founded in 2019 that combines in-house data analytics with scientific and clinical expertise to identify transformative therapies. The firm uses a disciplined, data-driven approach and a proprietary Logos Analytics platform to model clinical data, assess likelihood of clinical success, and support comprehensive underwriting, ongoing event tracking, and proactive risk management. Its team spans medical, scientific, and business disciplines, with the aim of delivering long-term returns through investments in therapies that have the potential to improve patient outcomes and redefine standards of care.

Mayo Clinic is a nonprofit medical practice, research, and education organization based in Rochester, Minnesota, with campuses in Arizona, Florida, and abroad. Founded in the 19th century, it provides comprehensive medical care across a wide range of specialties, supports medical education in clinical medicine and biomedical sciences, and conducts extensive biomedical research. The organization emphasizes patient-centered care, clinical excellence, and collaboration among physicians, scientists, and educators. Mayo Clinic also operates Mayo Clinic Platform, an initiative that builds a data- and AI-enabled ecosystem to connect clinical data, developers, and providers, supporting research, digital health tools, and innovation through partnerships with health tech companies and academic institutions. Mayo Clinic Ventures, the corporate venture arm, funds and translates inventions and discoveries into patient care. As a nonprofit enterprise, Mayo Clinic relies on philanthropy and diversified funding to advance care, education, and research while pursuing global collaborations and international programs.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

European Investment Fund is the EU's financing arm for small and medium-sized enterprises and mid-caps, providing financial instruments to improve access to affordable financing across businesses throughout their lifecycle. It focuses on supporting innovation, growth, competitiveness, social impact, and sustainability across the EU, including funding for infrastructure investments. By leveraging its capital base, the EIF fosters public-private partnerships to amplify investment and shares risk with banks, funds, and other partners to mobilize lending to SMEs and equity funding for startups through guarantees and equity instruments across EU member states, candidate countries, and EFTA states.

Samsung Electronics is a global technology company headquartered in South Korea that designs, manufactures, and markets a broad portfolio of consumer electronics, IT and mobile devices, and advanced components. The company sells smartphones, tablets, televisions, home appliances, printers, and PCs, and supplies memory and storage products, semiconductors, displays, and telecommunications infrastructure. It operates a leading semiconductor business and a dominant memory chip and display supply chain, supported by a wide network of global research and development efforts focused on AI, 5G, energy storage, and next generation materials. Samsung Electronics coordinates manufacturing, services, and repair capabilities and engages in open innovation with startups and academic partners through its research centers and corporate venture initiatives. It pursues growth across consumer, enterprise, and industrial segments and aims to deliver integrated device solutions and services worldwide, with emphasis on sustainability and governance to create long-term value for customers, employees, and society.

HBM Healthcare Investments is a Swiss investment firm founded in 2001 that focuses on delivering access to a globally diversified portfolio of healthcare companies. Headquartered in Switzerland, the firm targets opportunities across human medicine, biotechnology, medical technology and diagnostics, investing in both private and public companies with established or near-market products. It emphasizes active portfolio management and provides strategic guidance to portfolio companies to support value creation. By leveraging demographic trends and medical innovation, the firm seeks attractive returns while maintaining a diversified asset mix that includes private holdings, public equities and funds. The company is noted for an attractive dividend policy with a yield around five percent.

Lux Capital is a venture capital firm focused on investing in companies at the intersection of science, technology, and industry. The firm backs ventures applying research across sectors including artificial intelligence, biotechnology, advanced materials, space, and energy, with an emphasis on translating complex innovations into scalable businesses. Lux provides capital together with strategic input on product development, company building, and long-term positioning, and takes an active role to help founders navigate technical and market challenges. The firm evaluates opportunities based on the underlying science, potential industry impact, and feasibility of execution over extended horizons. With offices in New York and Silicon Valley, Lux collaborates with technical founders, researchers, and teams to build durable market leaders and accelerate scientific breakthroughs into real-world applications.

Casdin Capital is a New York-based investment firm focused on the life sciences and healthcare sectors. It targets biotechnology, genomics, precision medicine, oncology, digital health, and related technologies, applying data-driven, research-intensive analysis to identify disruptive opportunities in the field. The firm makes private investments across stages and seeks to partner with companies developing innovative therapies, diagnostics, and tools that advance healthcare. Founded in 2012 by Eli Casdin, Casdin Capital operates as a registered investment adviser and emphasizes a long-term, fundamental approach to identifying paradigm shifts in life sciences.

Korea Investment Partners is a venture capital and private equity firm headquartered in Seoul with additional offices in Shanghai, Beijing, and Sunnyvale. With over three decades of investment experience, it supports technology-driven entrepreneurs and companies across sectors including information technology, healthcare, life sciences, manufacturing and infrastructure. The firm manages multiple venture and private equity funds and leverages the Korea Investment Holdings network to provide strategic guidance and capital to portfolio companies worldwide.

TCG Crossover is a science-driven venture capital firm focused on healthcare and biotechnology. It invests in biotechnology and pharmaceutical companies across the United States and Europe, supporting the development of medicines through a network of scientific advisors and resources that help navigate clinical and regulatory challenges. The firm has teams in Palo Alto and New York City and pursues long-term partnerships with entrepreneurs to translate cutting-edge science into meaningful patient outcomes.

Omega Funds is a Boston-based venture capital firm founded in 2004 that focuses on early-stage investments in healthcare and biotech. It backs companies across biotechnology, pharmaceuticals, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, with activity in North America and Western Europe. The firm manages multiple funds and operates as a registered investment adviser, leveraging its network to support entrepreneurs and advance innovations in medicine and related technologies.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in building and funding early-stage biotechnology and life sciences companies, as well as technology ventures. Founded in 1980, it uses a seed-led venture creation approach to translate scientific discoveries into scalable medicines and biotech businesses, often acting as a lead investor and seeking board representation for portfolio companies.

Legend Capital is a Beijing-based venture capital firm and subsidiary of Legend Holdings, focused on backing high-growth Chinese technology and related companies. Since its inception in 2001, it has managed multiple funds totaling up to approximately US$700 million, investing primarily in early-stage IT ventures with operations centered in China or markets related to China. The firm targets sectors including network applications and services, outsourcing and professional services, and infrastructure such as IC design and key components, as well as mid-market growth companies in consumer goods, clean technology, healthcare, equipment manufacturing, and modern services. Legend Capital actively supports portfolio companies with resources for business development and market execution in China to create value and maximize returns. Notable portfolio companies have included Joyo.com, SinoCom, Solarfun Power, Spreadtrum Communications, China Sunshine Paper, VanceInfo, and Eyang. Legend Capital operates as a Beijing-based venture capital investor with a broad focus on technology-enabled sectors and China-linked opportunities.